Overall results of immune tolerance induction using recombinant factor VIII Fc fusion protein (rFVIIIFc) prospectively in 16 patients with severe hemophilia A and high-titer inhibitors (historical peak ≥5 Bethesda units per mL). Dosing was for up to 48 weeks. Patients achieving immune tolerance, according to negative inhibitor titer, in vivo recovery, and half-life, entered tapering and follow-up for ≥16 and 32 weeks, respectively. Boxes in green denote aspects specific for this study (ie, use of rFVIIIFc and short time to success). Treatment was well tolerated.